GlassScriptPhysician profile
Hannah Kalantari
NPI 1093356495
$3,944.48
in general payments reported to CMS, 2019-2025
26 companies · $753 in 2025
The $753 reported for 2025 was more than what 82% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,196 · 2022: $345 · 2023: $652 · 2024: $997 · 2025: $753.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,403.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,402.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $632.29 | 2021-2025 | Breztri, Farxiga |
| Abbvie INC. | $416.52 | 2021-2025 | |
| Pfizer INC. | $301.85 | 2024-2025 | |
| Lilly USA, LLC | $268.14 | 2021-2025 | Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $261.18 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Si-Bone, INC. | $256.94 | 2021 | |
| Janssen Pharmaceuticals, INC | $224.33 | 2024-2025 | Spravato |
| Novo Nordisk INC | $214.09 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Eisai INC. | $178.90 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $144.39 | 2024-2025 | Rexulti |
| Inspire Medical Systems, INC. | $124.10 | 2022 | |
| Neurocrine Biosciences, INC. | $114.08 | 2023 | |
| Almatica Pharma LLC | $108.60 | 2024-2025 | Loreev Xr, Teriparatide |
| Angiodynamics, INC. | $104.17 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $100.27 | 2025 | Caplyta |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $73.15 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Lundbeck LLC | $63.27 | 2024-2025 | Rexulti, Vyepti |
| Takeda Pharmaceuticals U.S.A., INC. | $59.22 | 2021-2024 | Trintellix |
| Axsome Therapeutics, INC. | $57.28 | 2025 | Symbravo |
| Scilex Pharmaceuticals INC. | $54.97 | 2024 | |
| Intuitive Surgical, INC. | $51.94 | 2022 | |
| Daiichi Sankyo INC. | $46.60 | 2024-2025 | Injectafer |
| Teva Pharmaceuticals USA, INC. | $42.02 | 2023-2025 | Austedo Xr, Austedo Xr |
| Bayer Healthcare Pharmaceuticals INC. | $16.82 | 2024 | |
| Currax Pharmaceuticals LLC | $15.11 | 2024 | Contrave |
| Boston Scientific Corporation | $14.25 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hannah Kalantari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.